Overview

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

Status:
Recruiting

Trial end date:
2022-02-04

Target enrollment:

Participant gender:

Summary

This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine. Participants will use continuous glucose monitoring (CGM) (Freestyle Libre 14-day system) during the study.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Insulin Glargine